With new drugs requiring over a decade to develop at a cost of billions of dollars, today’s drug manufacturers are under pressure to move products to market faster. But, to do this, pharmas must first overcome the key challenges that prevent them from putting more of their data to use, including:

  • Difficulty managing high volumes of variable data
  • Slow and arduous data integration processes
  • Data governance and security across collaborative efforts

Data silos are the source of these problems—leading to fragmented processes and critical information gaps across every stage of the drug lifecycle.

From R&D to supply chain, pharmacovigilance, and real world evidence generation—MarkLogic is enabling pharmas to rapidly ingest, access, and achieve insight from all of their pharmaceutical data at less cost.

提供開始

The MarkLogic Pharma Research Hub

A single pane of glass that provides easy access to the widest possible array of R&D data available, the Hub delivers 10X faster pharma data integration to advance collaboration and discovery.

詳細はこちら

With MarkLogic, we can provide data to researchers faster, more affordably and more accurately than our competitors.”

Phil Hajduk
ライフサイエンス向けソリューション

Bring Together All Your Pharma Data at Less Time and Cost

AbbVie Meets the Future with a Proud History of Innovation

IDC Customer Spotlight: AbbVie faces its own share of data challenges in R&D. A recent report by IDC offers insight into the issues and the next-generation database technology AbbVie’s using to overcome them.

Advance Drug Discovery With the R&D Platform of the Future

After FDA approval, a drug manufacturer must still prove the value of its drug to patients, providers, and payers. MarkLogic’s future-ready, agile data technology helps pharmas shorten development cycles to accelerate the development of new drugs.

Accelerate Detection of Adverse Events

MarkLogic’s operational data hub enhances detection of adverse events at every point in the drug lifecycle—empowering pharmas to avoid regulatory roadblocks and costly fines while protecting their reputations with both patients and regulators.

ポイントツーポイントが的外れな理由

成功するには、すべてのデータを見えるようにすることが必要

Expand beyond inefficient point-to-point SOA data integration to unify all of your pharma data at less time and cost. MarkLogic’s operational data hub gives pharmaceutical companies the ability to streamline operations—from R&D to the supply chain—powering innovation and operational efficiency.

詳細はこちら

ソリューション、RWE、ポイントツーポイント600
複数のスキーマ:1つのプラットフォーム

シームレスで洗練されたデータ統合

混合データも自然に処理して、分断されたデータサイロの統合を可能にするデータ管理の進化については、マルチモデルデータベースに関する無料のeBookをご覧ください。

マルチモデルのeBookを読む

グローバルなバイオテクノロジーリーダーがメタデータアプリケーションでRWEを加速

MarkLogicでは、バイオテクノロジーのグローバルリーダー向けにメタデータのカタログを作成しました。これにより、研究者はメタデータを使用して、調査対象に最も関連する患者の候補者や研究に関するデータセットを効率的に絞り込み、迅速なインサイトと競争上の優位性を発揮できるようになりました。

詳細はこちら

バイオテクノロジー600
Better Adverse Event Detection and Reporting

Pharmas seek to improve adverse event detection and reporting. But, as the volume of available real world data continues to grow, it becomes increasingly difficult to operationalize it. Harmonization, semantic enrichment, and making all data searchable are the first key steps to signal detection and critical insights.

Digitalizing the Modern Life Sciences Supply Chain

Amgen’s Dr. Clare Augustine, Taxonomy Management Lead, joins MarkLogic Healthcare, Life Sciences, and Manufacturing experts to discuss how industry-leading companies are connecting data from across the supply chain to improve lane carrier operations and compliance—at less cost.

MarkLogicによる機能強化
当ウェブサイトではクッキーを使用しています。

当Webサイトを継続利用することにより、お客様はMarkLogicのプライバシーステートメントに従ってクッキーの使用に同意するものとします。